FAME II - Fractional Flow Reserve (FFR) Guided Percutaneous Coronary Intervention (PCI) Plus Optimal Medical Treatment (OMT) Verses OMT
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01132495 |
Recruitment Status :
Completed
First Posted : May 28, 2010
Results First Posted : December 9, 2016
Last Update Posted : September 16, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Coronary Artery Disease | Other: Stenting plus OMT Other: OMT Other: Standard of care | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 1170 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | Fractional Flow Reserve-Guided Percutaneous Coronary Intervention Plus Optimal Medical Treatment Versus Optimal Medical Treatment Alone in Patients With Stable Coronary Artery Disease |
Study Start Date : | May 2010 |
Actual Primary Completion Date : | January 2014 |
Actual Study Completion Date : | May 2015 |

Arm | Intervention/treatment |
---|---|
Cohort A: PCI plus OMT
PCI plus optimal medical treatment
|
Other: Stenting plus OMT
FFR guided PCI, plus OMT |
Cohort A: OMT alone
Optimal medical treatment alone
|
Other: OMT
OMT alone |
Cohort B
FFR > 0.80; treatment according to local practice
|
Other: Standard of care
FFR > 0.80; treatment according to local practice |
- Major Adverse Cardiac Event Rate (MACE) [ Time Frame: 24 Month ]MACE: A composite of all cause death, documented MI, unplanned hospitalization leading to urgent revascularization.
- Overall MACE [ Time Frame: 3 years ]Individual components of the primary end point, cardiac death, and nonurgent revascularization

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Patients with
- stable angina or,
- stabilized angina pectoris or,
- atypical chest pain or no chest pain but with documented silent ischemia
- at least one stenosis is present of at least 50% in one major native epicardial coronary artery and supplying viable myocardium
- Eligible for PCI
- Signed written informed consent
Exclusion Criteria:
- Patients in whom the preferred treatment is CABG
- Patients with left main coronary artery disease requiring revascularization
- Patients with a recent STEMI or Non-STEMI
- Prior CABG
- Contra-indication to dual antiplatelet therapy
- LVEF < 30%
- Severe LV hypertrophy
- Planned need for concomitant cardiac surgery
- Extremely tortuous or calcified coronary arteries precluding FFR measurements
- A life expectancy of less than 2 years
- Age under 21

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01132495

Principal Investigator: | Bernard De Bruyne, MD | O.L.Vrouwzlekenhuis Hospital |
Responsible Party: | Abbott Medical Devices |
ClinicalTrials.gov Identifier: | NCT01132495 |
Other Study ID Numbers: |
0904 |
First Posted: | May 28, 2010 Key Record Dates |
Results First Posted: | December 9, 2016 |
Last Update Posted: | September 16, 2019 |
Last Verified: | August 2019 |
Stable angina angina pectoris PCI FAME |
FAME II FFR Fractional Flow Reserve Pressure wire |
Coronary Artery Disease Myocardial Ischemia Coronary Disease Heart Diseases |
Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases |